Beijing Wantai Biological Pharmacy Enterprise Co Ltd (SHSE:603392) Share Price

Company Profile

Business description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
Contact
No. 31, Science Park Road
Changping District
Beijing102206
CHN
T: +86 1059528888
https://www.ystwt.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4,116

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,047.30	25.90	-0.29%
CAC 40	8,421.14	46.84	-0.55%
DAX 40	24,985.82	40.98	-0.16%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,363.27	36.43	-0.35%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,250.06	196.57	0.28%
NZX 50 Index	13,495.63	132.32	0.99%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,828.70	27.90	-0.32%
SSE Composite Index	4,090.48	17.59	-0.43%